• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    J&J, Abbott Labs And JPM Among Jim Cramer's Top Picks As Market Shifts Focus From Tech

    7/21/23 6:07:23 AM ET
    $ABT
    $BFC
    $J
    $JPM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $ABT alert in real time by email

    As the market begins to shift its focus away from tech, CNBC’s Jim Cramer has identified several potential winners, CNBC reports.

    Cramer has highlighted a few sectors that could benefit from this shift. He believes that the market is currently in a “stock picker’s market” phase, where individual stocks are more likely to outperform than the broader market.

    See Also: J&J Investors Will Soon Be Able to Exchange Shares for Kenvue Stocks

    Among his top picks are the industrials, which he believes are poised for a comeback. Cramer identified stocks in the healthcare sector, particularly those of Johnson & Johnson (NYSE:J, J))) and Abbott Labs (NYSE:ABT)

    He also sees potential in the financial sector, particularly in banks, which could benefit from higher interest rates. Some of them include JP Morgan (NYSE:JPM), Wells Fargo (NYSE:WFC) and Bank of America (NYSE:BFC)

    Additionally, he suggests looking at the utilities sector.

    However, Cramer warns investors to be cautious and do their homework before investing in these sectors. He emphasizes the importance of understanding the fundamentals of a company and its industry before making an investment decision.

    Read Next: Mark Cuban Says Powerball Player Who Won $1.08B Jackpot Should Do This Next

    Image via Shutterstock


    Engineered by Benzinga Neuro, Edited by Pooja Rajkumari


    The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $BFC
    $J
    $JPM

    CompanyDatePrice TargetRatingAnalyst
    Wells Fargo & Company
    $WFC
    4/1/2026$94.00Hold → Buy
    HSBC Securities
    Wells Fargo & Company
    $WFC
    3/26/2026$100.00Buy
    Jefferies
    JP Morgan Chase & Co.
    $JPM
    3/26/2026$310.00Hold
    Jefferies
    Wells Fargo & Company
    $WFC
    2/13/2026$85.00Underperform → Neutral
    Robert W. Baird
    JP Morgan Chase & Co.
    $JPM
    2/3/2026$280.00Underperform → Neutral
    Robert W. Baird
    JP Morgan Chase & Co.
    $JPM
    1/7/2026Outperform → Peer Perform
    Wolfe Research
    Wells Fargo & Company
    $WFC
    1/6/2026$90.00Neutral → Underperform
    Robert W. Baird
    Jacobs Solutions Inc.
    $J
    11/24/2025$158.00Buy
    Goldman
    More analyst ratings

    $ABT
    $BFC
    $J
    $JPM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BFC
    $J
    $JPM
    SEC Filings

    View All

    SEC Form FWP filed by JP Morgan Chase & Co.

    FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

    4/3/26 2:49:49 PM ET
    $JPM
    Major Banks
    Finance

    SEC Form FWP filed by JP Morgan Chase & Co.

    FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

    4/3/26 9:39:49 AM ET
    $JPM
    Major Banks
    Finance

    SEC Form 424B3 filed by JP Morgan Chase & Co.

    424B3 - JPMORGAN CHASE & CO (0000019617) (Filer)

    4/2/26 4:32:22 PM ET
    $JPM
    Major Banks
    Finance

    $ABT
    $BFC
    $J
    $JPM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Georgia Cleantech Innovation Hub Awarded $600,000 by JPMorganChase to Strengthen Atlanta's Clean Tech Talent and Startup Ecosystem

    Two-Year Grant Funds Experiential Learning at Atlanta Universities and Planning for the City's First Build‑and‑Test Space for Clean Tech Startups ATLANTA, April 1, 2026 /PRNewswire/ -- Today, Georgia Cleantech Innovation Hub announced a new initiative with support from JPMorganChase, including a $600,000 philanthropic commitment to the Georgia Cleantech Innovation Hub (GACIH) to build the workforce and infrastructure needed to grow and scale clean technologies and businesses that save energy and water, cut waste, improve efficiency and reduce pollution—creating new opportunities for innovation, skilled jobs, and long‑term cost savings across the economy

    4/1/26 6:00:00 AM ET
    $JPM
    Major Banks
    Finance

    J.P. Morgan Private Capital Expands Team with Senior Hires

    Rand Araskog joins as Partner from PermiraEric Ghernati transitions to Partner role from J.P. Morgan Asset Management U.S. Equity GroupNEW YORK, March 31, 2026 /PRNewswire/ -- J.P. Morgan Private Capital, the venture and growth equity investment arm within J.P. Morgan Asset Management, today announced the appointments of Rand Araskog and Eric Ghernati as Partners focused on investing in leading growth companies. The team's expansion comes in response to a fundamental shift in capital markets. Companies are staying private for longer, with the median age at IPO of U.S. tech compa

    3/31/26 8:30:00 AM ET
    $JPM
    Major Banks
    Finance

    JPMorganChase Launches American Dream Initiative to Expand Local Economic Opportunity

    Initiative will kick off with expanded support to help 10 million small businesses thrive, up from seven million served today Efforts will accelerate and scale proven local solutions that advance small business growth, increase affordable housing, improve financial health, help people secure good jobs, expand access to quality healthcare and strengthen local institutions JPMorganChase today announced the American Dream Initiative (ADI)—a multi-year effort to help expand opportunity to millions of Americans and future generations through targeted investments in local communities across the United States. Building on years of advancing local solutions that deliver results, the firm will s

    3/31/26 6:00:00 AM ET
    $JPM
    Major Banks
    Finance

    $ABT
    $BFC
    $J
    $JPM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Starks Daniel J bought $1,087,331 worth of Common shares without par value (10,000 units at $108.73), increasing direct ownership by 0.15% to 6,738,817 units (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    2/6/26 8:04:16 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sprang Todd A. bought $21,159 worth of shares (150 units at $141.06), increasing direct ownership by 15% to 1,158 units (SEC Form 4)

    4 - Bank First Corp (0001746109) (Issuer)

    1/30/26 6:12:11 PM ET
    $BFC
    Major Banks
    Finance

    CHAIRMAN AND CEO Ford Robert B bought $2,013,967 worth of Common shares without par value (18,800 units at $107.13) (SEC Form 4)

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    1/26/26 8:02:24 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BFC
    $J
    $JPM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Wells Fargo from Hold to Buy and set a new price target of $94.00

    4/1/26 8:15:57 AM ET
    $WFC
    Major Banks
    Finance

    Jefferies initiated coverage on Wells Fargo with a new price target

    Jefferies initiated coverage of Wells Fargo with a rating of Buy and set a new price target of $100.00

    3/26/26 8:52:50 AM ET
    $WFC
    Major Banks
    Finance

    Jefferies initiated coverage on JPMorgan Chase with a new price target

    Jefferies initiated coverage of JPMorgan Chase with a rating of Hold and set a new price target of $310.00

    3/26/26 8:49:56 AM ET
    $JPM
    Major Banks
    Finance

    $ABT
    $BFC
    $J
    $JPM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Stratton John G

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:31:52 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Roman Michael F

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:24:18 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Gonzalez Patricia Paola

    4 - ABBOTT LABORATORIES (0000001800) (Issuer)

    4/2/26 5:15:44 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $BFC
    $J
    $JPM
    Leadership Updates

    Live Leadership Updates

    View All

    JPMorganChase Partners With Sports Legends to Help Athletes Master Their Money

    Athlete Council to guide JPMorganChase in new programs for athletes JPMorganChase today announced a new initiative to help athletes navigate every aspect of their financial lives, from early career stages through retirement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318551874/en/Names listed in photo order from left to right for each row. Building on the firm's extensive banking and wealth planning and management expertise, the JPMorganChase Athlete Council brings together some of the world's most accomplished sports figures who will meet with JPMorganChase leaders on a periodic basis to discuss the unique financial ne

    3/18/26 12:30:00 PM ET
    $JPM
    Major Banks
    Finance

    J.P. Morgan Asset Management Bolsters Commitment to Private Wealth Alternatives with Senior Hires

    Stephanie Davis joins as Head of Private Wealth Alternatives from Hamilton LaneSean Flynn tapped as Private Wealth Alternatives National Manager  NEW YORK, March 3, 2026 /PRNewswire/ -- J.P. Morgan Asset Management today announced the appointment of Stephanie Davis as Head of Private Wealth Alternatives, leading an increased focus on serving financial advisors across the U.S. Stephanie brings three decades of experience, most recently as Co-Head of U.S. Private Wealth Solutions at Hamilton Lane. Based in New York, she will report to Steve Lundquist, Head of U.S. Advisor. In her

    3/3/26 9:30:00 AM ET
    $JPM
    Major Banks
    Finance

    J.P. Morgan Asset Management Welcomes Pam Hess as Retirement Strategist

    Experienced retirement research expert to help meet increased demand for actionable retirement insights NEW YORK, Jan. 27, 2026 /PRNewswire/ -- J.P. Morgan Asset Management today announced the appointment of Pam Hess as Executive Director and Retirement Strategist on the Retirement Insights team reporting to Michael Conrath, Chief Retirement Strategist. This key hire reflects the firm's ongoing commitment to investing in resources that help financial professionals, participants and plan sponsors navigate today's complex retirement landscape. In this role, Pam supports the deve

    1/27/26 10:00:00 AM ET
    $JPM
    Major Banks
    Finance

    $ABT
    $BFC
    $J
    $JPM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jacobs Solutions Inc.

    SC 13G/A - JACOBS SOLUTIONS INC. (0000052988) (Subject)

    11/13/24 12:52:42 PM ET
    $J
    Military/Government/Technical
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bank First Corporation

    SC 13G/A - Bank First Corp (0001746109) (Subject)

    11/12/24 1:27:59 PM ET
    $BFC
    Major Banks
    Finance

    SEC Form SC 13G filed by Wells Fargo & Company

    SC 13G - WELLS FARGO & COMPANY/MN (0000072971) (Subject)

    11/12/24 10:40:28 AM ET
    $WFC
    Major Banks
    Finance

    $ABT
    $BFC
    $J
    $JPM
    Financials

    Live finance-specific insights

    View All

    Abbott hosts conference call for first-quarter earnings

    ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical

    3/26/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abbott completes acquisition of Exact Sciences

    Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea

    3/23/26 8:50:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jacobs completes acquisition of the remaining stake in PA Consulting

    Strengthens integrated advisory and technology-enabled solutions across complementary client baseCompleted the acquisition of all PA shares not previously owned for upfront consideration of approximately £1.2 billion (approximately $1.6 billion)1Continue to expect transaction to be accretive to adjusted EPS2 in the first 12 months after closeDALLAS, March 23, 2026 /PRNewswire/ -- Accelerating its growth strategy to redefine the asset lifecycle, Jacobs (NYSE:J) has completed its acquisition of the remaining equity interest in PA Consulting, a leading innovation and transformation consultancy.Since Jacobs' strategic investment in March 2021, PA Consulting has contributed to Jacobs' growth in a

    3/23/26 6:45:00 AM ET
    $J
    Military/Government/Technical
    Industrials